Skip to main content
. 2024 May 28;10(2):e004007. doi: 10.1136/rmdopen-2023-004007

Figure 2.

Figure 2

Proportions of patients achieving CDAI LDA/remission and DAS28 (CRP) ≤3.2/<2.6 through 264 weeks (AO). Groups are by treatment sequence AO, without imputation for missing data. All patients in the PBO group who were not previously rescued were switched to UPA at week 26. Data points plotted here are shown in online supplemental table 9. ADA, adalimumab; AO, as observed; CDAI, Clinical Disease Activity Index; DAS28 (CRP), 28-joint Disease Activity Score based on C reactive protein; LDA, low disease activity; PBO, placebo; UPA, upadacitinib.